Cyclic GMP-phosphodiesterase inhibition does not alter cerebral oxygen consumption

Neurochemical Research

Volumn 21, Issue 1, 1996, Pages 41-46

  Wei, Hwu Meei ^a   Shah, Abhijit J ^a   Tse, James ^a   Chi, Oak Za ^a   Weiss, Harvey M ^b  

^a Heart and Brain Circulation Laboratory   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

cerebral blood flow; cerebral O 2 consumption; cyclic GMP; Cyclic GMP phosphodiesterase; zaprinast

Indexed keywords

CYCLIC GMP PHOSPHODIESTERASE; CYCLIC GMP PHOSPHODIESTERASE INHIBITOR; IODOPHENAZONE; OXYGEN; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG; ZAPRINAST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD FLOW; BRAIN CORTEX; BRAIN OXYGEN CONSUMPTION; CONTROLLED STUDY; ENZYME INHIBITION; INHIBITION KINETICS; MALE; MICROSPECTROPHOTOMETRY; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; REGULATORY MECHANISM;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; CEREBRAL CORTEX; CEREBROVASCULAR CIRCULATION; MALE; OXYGEN; OXYGEN CONSUMPTION; PHOSPHODIESTERASE INHIBITORS; PURINONES; RATS; SECOND MESSENGER SYSTEMS;

ANIMALIA;

EID: 0030002428     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02527670     Document Type: Article

References (35)

1. Lincoln T. M., and Cornwell T. L. 1993. Intracellular cyclic GMP receptor protein. FASEB J. 7:328-338.
2. Hartzell H. C. 1988. Regulation of cardiac ion channels by catecholamines, acetylcholine and second messenger systems. Prog. Biophys. Molec. Biol. 52:165-247.
3. Pandol S. J., and Schoeffield-Payne M. S. 1990. Cyclic GMP regulates free cytosolic calcium in the pancreatic acinar cell. Cell. Calcium. 11:477-486.
4. Hyman A. L., Kadowitz P. J., and Lippton H. L. 1989. Methylene blue selectively inhibits pulmonary vasodilator responses in cats. J. Appl. Physiol. 66:1513-1517.
5. Zhou H. L., and Torphy T. J. 1991. Relationship between cyclic guanosine monophosphate accumulation and relaxation of canine trachealis induced by nitrovasodilators. J. Pharmacol. Exp. Ther. 258:972-978.
6. Sagawa M., Koide T., and Takato M. 1992. BY-1949 elicits vasodilation via preferential elevation of cyclic GMP levels within the cerebral artery: possible involvement of endothelium-mediated mechanisms. Eur. J. Pharmacol. 215:57-62.
7. Graser T., and Vanhoutte P. M. 1991. Hypoxic contraction of canine coronary arteries: role of endothelium and cGMP. Am. J. Physiol. 261:H1769-H1777.
8. Arnold W. P., Mittal C. K., Katsuki S., and Murad F. 1977. Nitric oxide activates guanylate cyclase and increases guanosine 3′5′-cyclic monophosphate levels in various tissue preparation. Proc. Natl. Acad. Sci. USA 74:3203-3207.
9. Dirnagl U., Lindauer V., and Villringer A. 1993. Role of nitric oxide in the coupling of cerebral blood flow to neuronal activation in rats. Neurosci. Lett. 149:43-46.
10. Goadsby P. J., Kaube H., and Hoskin K. L. 1992. Nitric oxide synthesis couples cerebral blood flow and metabolism. Brain Res. 595:167-170.
11. Cotman C. W., Bridges R. J., Taube J. S., Clark A. S., Geddes J. W., and Monahan D. T. 1989. The role of NMDA receptors in central nervous system: plasticity and pathology. J. NIH Res. 1: 65-74.
12. Dawson V. L., Dawson T. M., London E. D., Bredt D. S., and Snyder S. H. 1992. A novel neuronal messenger molecule in the brain: the free radical nitric oxide. Ann. Neurol. 32:297-311.
13. Lee T. P., Kuo J. F., and Greengard P. 1972. Role of muscarinic cholinergic receptors in regulation of guanosine 3′:5′-cyclic monophosphate content in mammalian brain, heart muscle and intestinal smooth muscle. Proc. Natl. Acad. Sci. USA 69:3287-3291.
14. Nishizaki T., and Okada Y. 1988. Effects of excitatory amino acids on the oxygen consumption of hippocampal slices from guinea pig. Brain Res. 452:11-20.
15. Frandsen A., Andersen C. F., and Schousboe A. 1992. Possible role of cGMP in excitatory amino acid induced cytotoxicity in cultured cortical neurons. Neurochem. Res. 17:35-43.
16. Edelman G. M., and Gaily J. A. 1992. Nitric oxide: linking space and time in the brain. Proc. Natl. Acad. Sci. USA 89:11651-11652.
17. G-nitro-L-arginine influences cerebral metabolism in awake sheep. J. Appl. Physiol. 73:2233-2240.
18. Merkel L. A., Rivera L. M., Perrone M. H., and Lappe R. W. 1992. In vitro and in vivo interactions of nitrovasodilators and zaprinast a cGMP-selective phosphodiesterase inhibitor. Eur. J. Pharmacol. 216:29-35.
19. Weiss H. R., Rodriguez E., Tse J., and Scholz P. M. 1994. Effect of increased myocardial cyclic GMP induced by cyclic GMP-phosphodiesterase inhibition on oxygen consumption and supply of rabbit hearts. Clin. Exp. Pharmacol. Physiol. 21:607-614.
20. McMahon E. G., Palomo M. A., Mehta P., and Olins G. M. 1989. Depressor and natriurctic effects of M&B 22948 a guanosine cyclic 3′5′-monophosphate-selective phosphodiesterase inhibitor. J. Pharmacol. Exp. Ther. 251:1000-1005.
21. Trapani A. J., Smits G. J., McGraw D. E., McMahon E. G., and Blaine E. H. 1991. Hemodynamic basis for the depressor activity of zaprinast a selective cyclic GMP-phosphodiesterase inhibitor. J. Pharmacol. Exp. Ther. 258:269-274.
22. 14C]-iodoantipyrine. Am. J. Physiol. 234:H59-H66.
23. Zhu N., and Weiss H. R. 1991. Oxy- and carboxyhemoglobin saturation in frozen small vessels. Am. J. Physiol. 260:H626-H631.
24. Tse J., Bracket N. L., and Kuo J. F. 1978. Alterations in activities of cyclic nucleotide systems in beta-adrenergic receptor-mediated activation of cAMP-dependent protein kinase during progression and regression of isoproterenol-induced cardiac hypertrophy. Biochem. Biophys. Acta. 542:399-411.
25. Komas N., Le Bec A., Stoclet J. C., and Lugnier C. 1991. Cardiac cGMP-stimulated cyclic nucleotide phosphodiesterase: effects of cGMP analogues and drugs. Eur. J. Pharmacol. 103:1973-1979.
26. Richards M. H. 1991. Pharmacology and second messenger interactions of cloned muscarinic receptors. Biochem. Pharmacol. 42: 1645-1653.
27. Luo D., Leung E., and Vincent S. R. 1994. Nitric oxide-dependent efflux of cGMP in rat cerebellar cortex: an in vivo microdialysis study. J. Neurosci. 14:263-271.
28. Harvey B., Carstens M., and Taljaard J. 1993. Absence of an effect of the lithium-induced increase in cyclic GMP on the cyclic GMP-stimulated phosphodiesterase (PDE II) Evidence for cyclic AMP-specific hydrolysis. Neurochem. Res. 18:1095-1100.
29. Murashima S., Tanaka T., Hockman S., and Manganiello V. 1990. Characterization of particulate cyclic nucleotide phosphodiesterases from bovine brain: purification of a distinct cGMP-stimulated isoenzyme. Biochem. 29:5285-5292.
30. Agullo L., and Garcia A. 1992. Different receptors mediate stimulation of nitric oxide-dependent cyclic GMP formation in neurons and astrocytes in culture. Biochem. Biophys. Res. Commun. 182:1362-1368.
31. Garthwaite J., Charles S. L., and Chess-Williams R. 1988. Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature 336:385-388.
32. Kurumaji A., and McCulloch J. 1989. Effect of MK-801 upon local cerebral glucose utilization in conscious rats and in rats anaesthetized with halothane. J. Cereb. Blood Flow Metab. 9:786-794.
33. Lu X., Yospin J., Wei H. M., and Weiss H. R. 1995. Effect of nitroprusside on cerebral regional cGMP blood flow and oxygen consumption in rat. FASEB J. 8:A27.
34. Chi, O. Z., Anwar M., Sinha A. K., Wei H. M., Klein, S. L., and Weiss H. R. 1992. Effect of isoflurane on transport across the blood-brain barrier. Anesthesiol. 76:426-431.
35. 2 saturation heterogeneity. Brain Res. 591:146-150.